TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $147,608 | -23.1% | 16,511 | +32.0% | 0.00% | 0.0% |
| Q2 2023 | $192,061 | -30.6% | 12,504 | +1.6% | 0.00% | 0.0% |
| Q1 2023 | $276,874 | +39.6% | 12,311 | +30.5% | 0.00% | 0.0% |
| Q4 2022 | $198,355 | +7.2% | 9,432 | +25.7% | 0.00% | 0.0% |
| Q3 2022 | $185,000 | +1.6% | 7,504 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $182,000 | -26.9% | 7,504 | -22.4% | 0.00% | 0.0% |
| Q1 2022 | $249,000 | -25.0% | 9,673 | -9.5% | 0.00% | -50.0% |
| Q4 2021 | $332,000 | +78.5% | 10,686 | +39.1% | 0.00% | +100.0% |
| Q3 2021 | $186,000 | +66.1% | 7,680 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $112,000 | -40.7% | 7,676 | +1.2% | 0.00% | 0.0% |
| Q1 2021 | $189,000 | -10.4% | 7,587 | -1.9% | 0.00% | 0.0% |
| Q4 2020 | $211,000 | – | 7,734 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |